Endothelin receptor antagonists - Their role in pulmonary medicine;Les antagonistes des récepteurs de l'endothéline: Leur place dans les maladies pulmonaires

Revue des Maladies Respiratoires

Volumn 26, Issue 10, 2009, Pages 1075-1090

  Boniface, S ^a   Reynaud Gaubert, M ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Ambrisentan; Bosentan; Endothelin receptor antagonists; Pulmonary arterial hypertension; Pulmonary fibrosis; Sitaxentan

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; SITAXSENTAN;

APOPTOSIS; CELL PROLIFERATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; HUMAN; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC SCLEROSIS; VASOCONSTRICTION;

EID: 74249112575     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0761-8425(09)73533-8     Document Type: Article

References (102)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T : A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 ; 332 : 411-5.
2. Humbert M, Sitbon O, Simonneau G : Treatment of pulmonary arterial hypertension. N Engl J Med 2004 ; 351 : 1425-36.
3. Dupuis J, Hoeper MM : Endothelin receptor antagonists in pulmonary hypertension. Eur Respir J 2008 ; 31 : 407-15.
4. Liu C, Chen J : Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of systematic reviews 2006. Issue 3. Art. No : CD004434.DOI : 10.1002/14651858.CD004434.pub3.
5. Galié N, Torbicki A, Barst R, Dartevelle P, Haworth S, Hig H, Peacok A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs M, Naeije R, Pepke-Zaba J : Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of cardiology. Eur Heart J 2004 ; 25 : 2243-78.
6. Inoue A, Yanangisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T : The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989 ; 264 : 14954-9.
7. Dao P, Montani D, Duong-Quy S, Dinh-Xuan AT : Signalisation cellulaire et physiopathologie de l'hypertension artérielle pulmonaire. Rev Mal Respir 2006 ; 23 : 3S75-83.
8. Eguchi S, Hirata Y, Imai T, Marumo F : Endothelin-1 as an autocrine growth factor for endothelial cells. J Cardiovasc Pharmacol 1995 ; 26 : S279-83 (suppl 3).
9. Stewart DJ, Levy RD, Cernacek P, Langleben D : Increased plasma endothelin-1 in pulmonary hypertension : marker or mediator of disease? Ann Intern Med 1991 ; 114 : 464-9.
10. Dupuis J : Endothelin receptor antagonists in pulmonary hypertension. Lancet 2001 ; 358 : 1113.
11. Dinh-Xuan AT : Endotheline-1 et physiopathologie de l'hypertension artérielle pulmonaire. Rev Mal Respir 2003 ; 20 : 6123-0.
12. Migneault A, Sauvageau S, Villeneuve L, Thorin E, Fournier A, Leblanc N, Dupuis J : Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxyde. Am J Respir Crit Care Med 2005 ; 171 : 506-13.
13. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morell NW, Wharton J : ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002 ; 165 : 398-405.
14. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F : Endothelin receptor subtype B mediates synthesis of nitric oxyde by cultured bovine endothelial cells. J Clin Invest 1993 ; 91 : 1367-73.
15. Dupuis J, Stewart DJ, Cernacek P, Gosselin G : Human pulmonary circulation is an important site of both clearance and production of endothelin-1.Circulation 1996 ; 94 : 1578-84.
16. Sauvageau S, Thorin E, Caron A, Dupuis J : Endothelin-1-induced pulmonary vaso reactivity is regulated by ETA and ETB receptor interactions. J Vasc Res 2007 ; 44 : 375-81.
17. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bhou-Gharios G, Pearson JD, Dashwood M, Du bois RM, Black CM, Leask A, Abraham DJ : Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Aktdependant pathway is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Cell Biol 2004 ; 15 : 2707-19.
18. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, du Bois RM, Black CM : Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997 ; 151 : 831-41.
19. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schäfers HJ : Selective up-regulation of endothelin b receptor gene expression in severe pulmonary hypertension. Circulation 2002 ; 105 : 1034-6.
20. Marie I, Bekri S, Lévesque H : Endothéline-1 et sélectivité des antagonistes des récepteurs de l'endothéline 1 : to B or not to B? Rev Med Interne 2008 : 263-8.
21. Opitz CF, Ewert R Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008 ; 29 : 1936-48.
22. Montani D, Jais X, Sitbon O, Capron F, Simonneau G, Humbert M : Hypertension artérielle pulmonaire. Rev Mal Respir 2005 ; 22 : 651-66.
23. Simonneau G, Galié N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S Leclerc D, Speich R, Beghetti M, Rich S, Fishman A : Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004 ; 43 : S5-12.
24. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesh DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Longleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Craw JM, the Primary Pulmonary Hypertension Study Group : A comparison of continues intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996 ; 334 : 296-302.
25. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ : Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension : a randomised placebo-controlled study. Lancet 2001 ; 358 : 1119-23.
26. Rubin LJ, Badesch DB, Barst RJ, Galié N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzgerg M, Simonneau G for the Bosenan Randomised Trial of Endothelin Antagonist Therapy Study Group : Bosentan therapy for pulmonary arterial hypertension (BREATHE-1). N Engl J Med 2002 ; 346 : 896-903.
27. Rubin LJ, Roux S : Bosentan : a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002 ; 11 : 991-1002.
28. Van Giersbergen PLM, Popescu G, Bodin F, Dingemanse J : Influence of mild liver impairement on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2003 ; 43 : 15-22.
29. Dingemanse J, Van Giersbergen PLM : Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int J Clin Pharmacol Ther 2002 ; 40 : 310-6.
30. Weber C, Banken L, Birnboeck H, Schulz R : Effect of the endothelinreceptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarine. J Clin Pharmacol 1999 ; 39 : 847-54.
31. Weber C, Banken L, Birnboeck H, Nave S, Schulz R : The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol 1999 ; 47 : 701-6.
32. Humbert M, Nunes H, Sitbon O, Parent F, Hervé P, Simonneau G : Risk Factors for pulmonary arterial hypertension. Clin Chest Med 2001 ; 22 : 459-75.
33. van Giersbergen PL, Halabi A, Dingemanse J : Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther. 2006 ; 44 : 113-8.
34. Humbert M, Barst RJ, Robbins IM, Channick RN, Galié N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G : Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004 ; 24 : 353-9.
35. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, Van Giersbergen PL : Pharmacokinetics, safety, and efficacy of bosentan in paediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003 ; 73 : 372-82.
36. Sitbon O, Gressin V, Speich R, MacDonald PS, Opravil M, Cooper DA, Fournme T, Humbert M, Delfraissy JF, Simonneau G : Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care med 2004 ; 170 : 1212-7.
37. Galié N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M, for the Bosentan randomised trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators : Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double-blind randomised, placebo-controlled study. Circulation 2006 ; 114 : 48-54.
38. Galié N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E, Kusic-Pajic A, Simonneau G : Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008 ; 371 : 2093-100.
39. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ : Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (BENEFiT) a randomised placebo-controlled trial. J Am Coll Cardiol 2008 ; 52 : 2127-34.
40. Sitbon O, Badesch DB, Channick R, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ : Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. A 1-year follow-up study. Chest 2003 ; 124 : 247-54.
41. Humbert M, Segal ES, Kiely DG, Carisen J, Schwierin B, Hoeper MM : Results of European post-marketing of bosentan in pulmonary hypertension. Eur Respir J 2007 ; 30 : 338-44.
42. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galié N, Rainisio M, Simonneau G, Rubin LJ : Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005 ; 25 : 244-49.
43. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G : Long-term outcome with first-line bosentan therapy in idiopathic pulmonary hypertension. Eur Heart J 2006 ; 27 : 589-95.
44. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galié N, Humbert M, Rainisio M, Rubin LJ, Simonneau G : Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on intravenous epoprostnol. Thorax 2005 ; 60 : 1025-30.
45. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV : Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice Guidelines. Chest 2007 ; 131 : 1917-28.
46. Denton CP, Humbert M, Rubin L, Black CM : Bosentan treatment for pulmonary arterial hypertension related to connective disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006 ; 65 : 1336-40.
47. Mukerjee D, StGeorges D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG : Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003 ; 62 : 1088-93.
48. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE : Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003 ; 123 : 344-50.
49. Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, Van den Hoogen FH, Riemekasten G, De Vita S, Morganti A, Dölberg M, Berkani O, Guillevin L (on behalf of the TRacleer Use in PAH associated with scleroderma and Connective Tissue Diseases (TRUST Investigators) : Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue disease. Ann Rheum Dis 2008 ; 67 : 1222-8.
50. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J : Bosentan therapy for porto pulmonary hypertension. Eur Respir J 2005 ; 25 : 502-8.
51. Jais X, Dartevelle P, Parent F, Sitbon O, Humbert M, Fadel E, Mussot S, Cabrol S, Le Pavec J, Sztrymf B, Tcherakian C, Musset D, Maitre S, Simonneau G : Hypertension pulmonaire postembolique. Rev Mal Respir 2007 ; 24 : 497-508.
52. Chaouat A, Canuet M, Gomez E, Chabot F, Weitzenblum E : Hypertension pulmonaire des affections respiratoires chroniques. Rev Mal Respir 2007 ; 24 : 509-21.
53. Hoeper MM, leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J : Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur respir J 2006 ; 28 : 691-4.
54. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ : Randomised study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006 ; 174 : 1257-63.
55. Galié N, Gruenig E, Vachiery JL, Vizza CD, Michelakis E : NTproBNP plasma levels correlate with baseline exercice capacity and hemodynamics in treated PAH patients : analysis of COMPASS-1 Study data. ATS 2008, A260.
56. Effects of the combination of Bosentan and Sildenafil monotherapy on pulmonary arterial hypertension (Compass2), NCT 00303459, Clinicaltrials. gov.
57. Burgess G, Hoogkamer H, Collins L, Di gemanse J : Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008 ; 64 : 43-50.
58. Cheng JWM : Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008 ; 30 : 825-33.
59. Barst RJ : A review of pulmonary hypertension : role of ambrisentan. Vasc health and Risk Mana 2007 ; 3 : 11-22.
60. Dufton C Gerber MJ, Yin O : Non clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest 2006 ; 130 : S254 (Suppl 4).
61. Gerber MJ, Dufton C, Pentikis H : Ambrisentan has not clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Chest 2006 ; 130 : S256 (Suppl 4).
62. Galié N, Badesch DB, Oudiz RJ, Simonneau G, McGoon MD, Keog AM, Frost A, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ : Ambrisentan Therapy of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2005 ; 46 : 529-35.
63. Galié N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ : Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomised, Double-Blind, Placebo-Controlled, Multicenter Efficacy (ARIES) Study 1 and 2. Circulation 2008 ; 117 : 0-10.
64. Cacoub P, Amoura Z, Langleben D : La prise en charge thérapeutique de l'hypertension artérielle pulmonaire par les antagonistes des récepteurs de l'endothéline en 2008. Rev Med Int 2008 ; 29 : 283-9.
65. Wu C, Chan MF, Stavros F, Raju B, Okun I, Mong S, Keller KM, Brock T, Kogan TP, Dixon RA : Discovery of TBC11251, a potent long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997 ; 40 : 1690-97.
66. Dhaun N, Melville V, Kramer W, Stavros F, Coyne T, Swan S, Goddard J, Webb DJ : The pharmacokinetic profile of sitaxentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment. Br J Clin Pharmacol 2007 ; 64 : 733-7.
67. Barst RJ, Rich S, Widlitz A, Hom EM, McLaughlin V, McFarlin J : Clinical efficacy of sitaxentan, an oral endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest 2002 ; 121 : 1860-8.
68. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N and the STRIDE-2 Study Group : Treatment of pulmonary arterial hypertension wtih the selective endothelin-receptor antagonist sitaxsentan. J Am Coll Cardiol 2006 ; 47 : 2049-56.
69. Coyne T, Dixon R : Warfarin management in pulmonary arterial hypertension is similar between bosentan, placebo, and sitaxentan. Chest 2005 ; 128 : S366.
70. Barst RJ, Langleben D, Frost A, Horm EM, Oudiz R, Shapiro S, McLaughlin VV, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RAF, Frumkin LR, and the STRIDE-1 Study Group : Sitaxentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 ; 169 : 441-7.
71. Oudiz RJ, Barst RJ, Hansen JE, Sun XJ, Garofano R, Wu X, Wasserman K : Cardiopulmonary exercice testing and six-minute correlations in pulmonary arterial hypertension. Am J Cardiol 2006 ; 97 : 123-6.
72. Benza R, Frost A, Girgis R : Chronic treatment of pulmonary arterial hypertension with sitaxentan and bosentan. Proc Am Thorac Soc 2006 ; 3 : A729.
73. Girgis RE, Frist AE, Hills NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ : Selective endothelin A receptor antagonism with sitaxentan for pulmonary arterial hypertension associated with cnnective tissue disease. Ann Rheum Dis 2007 ; 66 : 1467-72.
74. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ : Sitaxentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007 ; 26 : 63-9.
75. Piacentini L, Gray M, Honbo NY, Chentoufi J, Bergman M, Karliner JS : Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Moll Cell Cardiol 2000 ; 32 : 565-76.
76. Humbert M, Morel NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M : Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004 ; 43 : 13-24 (Suppl. 1).
77. Dhaun N, Pollock DM, Goddard J, Webb DJ : Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 2007 ; 28 : 573-9.
78. Kahaleh MB : Endothelin, an endothelial-dependant vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991 ; 34 : 978-83.
79. Kawaguchi Y, Suzuki H, Hara M, Hidaka T, Ishizuka T, Kawagoe M, Nakamura H : Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerois. Ann Rheum Dis 1994 ; 53 : 506-10.
80. Cambrey AD, Harrison NK, Dawes KE, Southcott AM, Black CM, du Bois RM, Laurent GJ, McAnulty RJ : Increased levels of endothelin-1in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Moll Biol 1994 ; 11 : 439-45.
81. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM : Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998 ; 31 Suppl 1 : S360-3.
82. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002 ; 65 : 277-304.
83. Richeldi L, Davies HR, Ferrara G, Franco F : Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No. : CD002880. DOI : 10.1002/14651858.CD002880.
84. Davies HR, Richeldi L, Walters EH : Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No. : CD003134. DOI : 10.1002/14651858.CD003134.
85. Cottin V : Traitement de la fibrose pulmonaire. Presse Med 2002 Oct 19 ; 31 : 1613-23.
86. Wells AU, Hirani N, British Thoracic Society, Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of care Committee ; Thoracic Society of Australia, New Zealand Thoracic Society ; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008 ; 63 Suppl 5 : v1-58.
87. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr and Idiopathic Pulmonary Fibrosis Study Group : A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004 ; 350 : 125-33.
88. Walter N, Collard HR, King TE Jr : Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006 ; 3 : 330-8.
89. A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in patients with idiopathic pulmonary fibrosis. ClinicalTrials.gov. NCT00131274.
90. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Tagushi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S : Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005 ; 171 : 1040-7.
91. Selman M, King TE Jr, Pardo A : Idiopathic pulmonary fibrosis : prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001 ; 134 : 136-51.
92. Selman M, Pardo A : Idiopathic pulmonary fibrosis: an epithelial: fibroblastic cross-talk disorder. Respir Res 2002 ; 3 : 3-10.
93. Horowitz JC, Thannickal VJ : Epithelial-mesenchymal interactions in pulmonary fibrosis. Sem Respir Clin Care Med 2006 ; 27 : 600-12.
94. Cottin V, Cordier JF : Bosentan et fibrose pulmonaire. Rev Med Intern 2007 ; 28 : S230-7.
95. Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, Ben-Efraim S, Spirer Z : Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstital lung diseases. Int J Immunopharmacol 1999 ; 21 : 759-75.
96. Shi-Wen W, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bougharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ : Endothelin-1 promotes myofibroblasts induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Aktdependant pathway and its essential for the enhanced contractile phenotype of fibrostic fibroblasts. Moll Biol Cell 2004 ; 15 : 2707-19.
97. Park SH, Saleh D, Giaid A, Michel RP : Increased endothelin-1 in bleomycin-I induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997 ; 165 : 600-8.
98. King TE Jr, Behr J, Brown KK, Du Bois RM, Lancaster L, de Andrade J, Stähler G, Leconte I, Roux S, Raghu G : BUILD-1: a randomised placebo-controlled trial of Bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008 ; 177 : 75-81.
99. Lynch DA, Behr J, Brown KK, du Bois RM, King TE Jr, Raghu G : High-resolution computed tomography (HRCT) features correlate with response to bosentan in idiopathic pulmonary fibrosis (IPF): the BUILD-1study. American Thoracic Society International Conference (2007), A567.
100. Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Event-Driven, Group Sequential, Phase III Study. ClinicalTrials.gov.NCT00391443.
101. Seibold JR, Black CM, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Chadha-boreham H, Charef P, Roux S : Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): the BUILD-2 study. Proc Am Thorac 2006 ; 3 : A243.
102. Battistini B, Berthaume N, Kelland NF, Webb DJ, Kohan DE : Profile of past and current clinical trials involving endothelin receptor antagonists : the Novel « -Sentan » class of drug. Exp Biol Med 2006 ; 231 : 653-95.